Not for distribution to U.S. Newswire Services or for dissemination in the United States. Any failure to comply with this restriction may constitute a violation of U.S. Securities laws.
TORONTO, ON / ACCESSWIRE / November 10, 2020 / Novamind Ventures Inc. (“Novamind”), a leading mental health and wellness company specialized in psychedelic-assisted psychotherapy, today announced its support for the recently passed Measure 109 in the State of Oregon, a citizen initiative to establish the first regulated and licensed program for psilocybin therapy in the United States.
“The passage of Measure 109 is a major milestone in the movement to regulate psychedelic medicine, and it paves the way for patients in Oregon and beyond to access psilocybin therapy in a safe and legal manner,” said Yaron Conforti, Chief Executive Officer and Director of Novamind. “We support responsible and measured initiatives to expand access to psychedelic medicine and look forward to working with healthcare professionals and key stakeholders in Oregon to contribute to The Psilocybin Mushroom Service Program for the ultimate benefit of patients seeking safe and regulated access to alternative mental health therapies.”
Novamind has clinical expertise in psychedelic-assisted psychotherapy that can enable the planning and execution of psilocybin treatments in Oregon, and across the country. Novamind clinicians are widely recognized for participation in leading clinical trials examining psychedelics, as well as their capabilities in delivering safe, legal experiences for patients utilizing ketamine in the United States. Cedar Psychiatry by Novamind, based in Utah, has administered over 3,000 ketamine-assisted psychotherapy treatments since 2016 across its four clinics in the State.
With the passing of Measure 109, the Oregon Health Authority is now authorized to create a program, subject to a two-year development timeline, that permits licensed service providers to administer psilocybin-producing mushroom and fungi products to individuals 21 years of age or older. Psilocybin will not be available commercially or for home-based use, and strict regulations ensure psilocybin will only be used in settings under the supervision of trained facilitators.
Novamind is building a global network of clinics, retreats and research sites to serve the regulated psychedelics industry. With our wholly-owned subsidiaries, Cedar Psychiatry and Cedar Clinical Research, Novamind is dedicated to providing access to safe and legal psychedelic experiences, while advancing research for psychedelic medicine.
For more information visit www.novamind.ca.
Yaron Conforti, CEO and Director
T: +1 (647) 953 9512